Loading clinical trials...

Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects | Clinical Trials | Clareo Health

COMPLETED

Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects

Qualitative Research to Explore Patient Preference for Modes of Administration in Pulmonary Arterial Hypertension Treatments

NCT03304548•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with an Angiotensin converting enzyme 2 (ACE2). This new treatment may require subcutaneous administration, in comparison to current treatments which are taken orally. Hence, GSK would like to conduct this qualitative interview study with PAH subjects to explore subject's perspective and preferences for various modes of treatment administration (daily or weekly subcutaneous injection versus current treatment options). This will be a qualitative study comprising the conduct of semi-structured telephone concept elicitation interviews with 8 to 10 PAH subjects (each approximately 30 minutes in duration) in the United States (US).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female, at least 18 years of age.
•Subject is willing and able to provide written informed consent.
•Subject must have a diagnosis of symptomatic Pulmonary Arterial Hypertension Type I as per the World Health Organization (WHO) clinical classification system.
•Subject must have the cognitive and linguistic capabilities sufficient to allow them to actively participate in an interview lasting 30 minutes.

Exclusion Criteria

•Subject has a diagnosis of other cardiac or pulmonary disease.
•Subject has a Type II-V diagnosis of PAH, as per the WHO clinical classification system.
•Subject is currently receiving treatment for PAH via modes of administration other than intravenously or orally.

Locations (1)

GSK Investigational Site

Boston, Massachusetts, United States

Key Dates

Start Date

November 22, 2017

Primary Completion Date

April 10, 2018

Completion Date

April 10, 2018

Last Updated

April 2, 2019

Enrollment

ACTUAL participants

Conditions

Hypertension, Pulmonary

Interventions

Telephone concept elicitation interview

OTHER

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

NCT07079592

Artificial Intelligence (AI)Artificial Intelligence (AI) in Diagnosis+1 more

View study

RECRUITINGNA

Functional Pulmonary Capillary Surface Area in BPA for CTEPH

NCT05719415

Hypertension, PulmonaryPulmonary Thromboembolisms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 2, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects

Inclusion Criteria

Exclusion Criteria

A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

Functional Pulmonary Capillary Surface Area in BPA for CTEPH

Real-World Study of PADN for the Treatment of PAH

Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)